Last edition
News about "Nona Biosciences "
Nona Biosciences and Valink Partner to Advance Biologics Discovery
Nona Biosciences and Valink Therapeutics have partnered to advance biologics discovery by combining Nona’s Harbour Mice fully human antibody technologies, including heavy chain-only antibodies, with Valink’s LiliumX discovery platform to generate and screen thousands of novel drug candidates.
Nona Biosciences | 18/12/2025 | By News Bureau
Nona Biosciences Taps Dr. Hongjiang Miao to Advance A3 Strategy and AI-Driven Drug Discovery
Dr. Hongjiang Miao will lead the Nona AI team to advance the company's A3 (Antibody engineering × AI × Automation) strategy and further transform Nona into an AI-driven drug discovery company.
Nona Biosciences | 04/12/2025 | By Dineshwori
Nona Biosciences and Umoja Biopharma Expand Partnership to Advance In-vivo CAR-T Therapies
Under the terms of the agreement, Nona Biosciences is eligible to receive an upfront payment, potential option exercise fees and milestone payments tied to the discovery and development of specific programmes in the collaboration. Umoja will be responsible for all further product development and commercialisation.
Nona Biosciences | 07/11/2025 | By Dineshwori | 146
Nona Biosciences, Kodiak Sciences to Power Next-Gen Antibody Therapies for Ophthalmic Diseases
The Harbour Mice platform generates fully human monoclonal antibodies in both the two heavy and two light chains (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization.
Nona Biosciences | 11/12/2024 | By Aishwarya | 276
Nona Biosciences Signs Partnership Deal with Alaya.bio to Advance CAR-T Cell Therapy
Nona Biosciences has entered into a collaboration agreement with Alaya. bio to precisely target and reprogram cells in situ and thus to significantly simplify the way CAR-T cell therapies in particular are being developed, manufactured and administered.
Nona Biosciences | 15/07/2024 | By Aishwarya | 472
Nona Biosciences Signs License Deal with AstraZeneca for Monoclonal Antibody Development
Nona Biosciences has signed a license deal with AstraZeneca for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.
Nona Biosciences | 27/05/2024 | By Aishwarya | 357
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy